Pay in 4 interest-free payments of $5.14 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
These thoughts are not facts
Still, they work through fundamentally different mechanisms: AOD-9604 is a modified fragment of human growth hormone designed to isolate its lipolytic (fat-metabolizing) region without triggering the broader GH/IGF-1 response, while Tesamorelin is a growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary to increase natural GH production
Due to their lack of association with hypoglycemia, positive effects on satiety and weight loss, and infrequency of administration, these GLP-1 analogues are now the first injectable medication of choice indicated by ADA guidelines for type-2 diabetics
Southlake patients in our wellness network reported 2x higher success rates in maintaining losses compared to solo efforts
Tirzepatide, on the other hand, is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist
Side-by-Side Comparison Parameter Receptors Cagrilintide AMY1R/2R/3R + CTR Semaglutide GLP-1R Tirzepatide GLP-1R + GIPR Retatrutide GLP-1R + GIPR + Glucagon-R Parameter Half-life Cagrilintide ~7-8 days Semaglutide ~7 days Tirzepatide ~5 days Retatrutide ~6 days Parameter Dosing frequency Cagrilintide Once weekly Semaglutide Once weekly Tirzepatide Once weekly Retatrutide Once weekly Parameter Max studied dose Cagrilintide 4.5 mg/week (mono) Semaglutide 2.4 mg/week Tirzepatide 15 mg/week Retatrutide 12 mg/week Parameter Peak monotherapy weight loss Cagrilintide 11.8% at 68 wk Semaglutide 14.9-17% at 68 wk Tirzepatide 22.5% at 72 wk Retatrutide ~24% at 48 wk Parameter FDA status (June 2026) Cagrilintide Investigational Semaglutide Approved (2021) Tirzepatide Approved (2023) Retatrutide Investigational Parameter HbA1c reduction (T2D) Cagrilintide ~0.9 pp mono
